{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:24:45Z","timestamp":1787840685114,"version":"build-2784847793"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"Abstract<\/jats:title>\n \n Background:<\/jats:title>\n We aimed to investigate the relationship between sarcopenia, which is defined by using psoas muscle index (PMI), and survival outcomes in patients with metastatic renal cell carcinoma (mRCC).<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n This is a retrospective descriptive study of mRCC treated with first-line anti-vascular endothelial growth factor (anti-VEGF) therapy. The prognostic significance of PMI for progression-free survival (PFS) and overall survival (OS) was evaluated by univariate and multivariate analyses. Additionally, the skeletal muscle index (SMI) was calculated and correlation analysis was performed between PMI and SMI.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Eighty-eight patients with a median age of 60 years (interquartile range [IQR], 51\u201366) were included. Median PFS with first-line treatment was 6 (95% confidence interval [CI]: 2.9\u20139.03) months and median OS was 17 (95% CI: 10.6\u201323.03) months in all patients. Mean PMI was 5.71 (standard deviation [SD]: \u00b11.41) in women and 8.30 (SD: \u00b12.04) in men. Forty-seven (53.4%) patients according to PMI and 49 (55.6%) patients according to SMI were accepted as sarcopenic. The overall correlation between SMI and PMI was strong (\n r<\/jats:italic>\n s = 0.73). PFS was numerically shorter in the low-PMI and low-SMI groups than the high-PMI and high-SMI groups, but it did not reach statistical significance. In univariate analyses, International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk score, anti-VEGF agent option, PMI, and SMI were significant prognostic factors for OS (\n P<\/jats:italic>\n < 0.05 each). In multivariate analyses for OS, while IMDC score (\n P<\/jats:italic>\n < 0.001) and PMI (\n P<\/jats:italic>\n = 0.04) were significant independent prognostic factors according to multivariate analysis-1, IMDC score (\n P<\/jats:italic>\n < 0.001) and SMI (\n P<\/jats:italic>\n = 0.01) were significant independent prognostic factors according to multivariate analysis-2.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Pretreatment PMI has a strong correlation with SMI and is an independent prognostic factor for OS in patients with mRCC.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijc.ijc_649_21","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T12:04:51Z","timestamp":1739793891000},"page":"789-796","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of psoas muscle index in metastatic renal cell carcinoma patients treated with anti-VEGF therapy"],"prefix":"10.4103","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2688-1515","authenticated-orcid":false,"given":"Rukiye","family":"Ar\u0131kan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2408-7660","authenticated-orcid":false,"given":"\u00d6zlem","family":"Demircio\u011flu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Marmara University School of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2790-7206","authenticated-orcid":false,"given":"Salih","family":"\u00d6zg\u00fcven","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Marmara University School of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6630-5278","authenticated-orcid":false,"given":"Naz\u0131m Can","family":"Demircan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6635-2012","authenticated-orcid":false,"given":"\u00d6zkan","family":"Alan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, Tekirdag State Hospital, Tekirdag, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6535-6030","authenticated-orcid":false,"given":"Tu\u011fba Ak\u0131n","family":"Telli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2726-1740","authenticated-orcid":false,"given":"Selver","family":"I\u015f\u0131k","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2059-5502","authenticated-orcid":false,"given":"Tu\u011fba","family":"Ba\u015fo\u011flu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6922-1018","authenticated-orcid":false,"given":"Abdussamed","family":"\u00c7elebi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8814-8947","authenticated-orcid":false,"given":"Alper","family":"Ya\u015far","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9879-5379","authenticated-orcid":false,"given":"Ceren \u00d6zge","family":"\u015eahin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Marmara University School of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5892-3519","authenticated-orcid":false,"given":"\u00d6zlem","family":"Ercelep","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6584-902X","authenticated-orcid":false,"given":"Faysal","family":"Dane","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, Ac\u0131badem University School of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8971-2076","authenticated-orcid":false,"given":"Canan","family":"Cim\u015fit","sequence":"additional","affiliation":[{"name":"Department of Radiology, Marmara University School of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8650-299X","authenticated-orcid":false,"given":"Perran Fulden","family":"Yumuk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, Koc University School of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"R1-20250217","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrurol.2010.46","article-title":"Epidemiology and risk factors for kidney cancer","volume":"7","author":"Chow","year":"2010","journal-title":"Nat Rev Urol"},{"key":"R2-20250217","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.eururo.2011.06.049","article-title":"The epidemiology of renal cell carcinoma","volume":"60","author":"Ljungberg","year":"2011","journal-title":"Eur Urol"},{"key":"R3-20250217","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"R4-20250217","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1200\/JCO.2005.05.179","article-title":"Validation and extension of the memorial sloan-kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma","volume":"23","author":"Mekhail","year":"2005","journal-title":"J Clin Oncol"},{"key":"R5-20250217","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1158\/1078-0432.CCR-11-0553","article-title":"Prognostic model for survival in patients with metastatic renal cell carcinoma:Results from the \u0131nternational kidney cancer working group","volume":"17","author":"Manola","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R6-20250217","doi-asserted-by":"crossref","first-page":"339.e17","DOI":"10.1016\/j.urolonc.2015.01.011","article-title":"Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma","volume":"33","author":"Sharma","year":"2015","journal-title":"Urol Oncol"},{"key":"R7-20250217","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia:Revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"key":"R8-20250217","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/annonc\/mdu086","article-title":"Validation of the consensus-definition for cancer cachexia and evaluation of a classification model\u2014A study based on data from an international multicentre project (EPCRC-CSA)","volume":"25","author":"Blum","year":"2014","journal-title":"Ann Oncol"},{"key":"R9-20250217","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/ageing\/afq034","article-title":"Sarcopenia:European consensus on definition and diagnosis:Report of the European Working Group on Sarcopenia in Older People","volume":"39","author":"Cruz-Jentoft","year":"2010","journal-title":"Age Ageing"},{"key":"R10-20250217","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jamda.2013.11.025","article-title":"Sarcopenia in Asia:Consensus Report of the Asian Working Group for Sarcopenia","volume":"15","author":"Chen","year":"2014","journal-title":"J Am Med Dir Assoc"},{"key":"R11-20250217","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jamda.2011.01.003","article-title":"Sarcopenia:An undiagnosed condition in older adults. current consensus definition:Prevalence, Etiology, and Consequences. International Working Group on Sarcopenia","volume":"12","author":"Fielding","year":"2011","journal-title":"J Am Med Dir Assoc"},{"key":"R12-20250217","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia:An international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"R13-20250217","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1139\/H08-075","article-title":"A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care","volume":"33","author":"Mourtzakis","year":"2008","journal-title":"Appl Physiol Nutr Metab"},{"key":"R14-20250217","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.nut.2016.04.003","article-title":"Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adults","volume":"32","author":"Hamaguchi","year":"2016","journal-title":"Nutrition"},{"key":"R15-20250217","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/jjco\/hyaa218","article-title":"Validity of measuring psoas muscle mass index for assessing sarcopenia in patients with gynecological cancer","volume":"51","author":"Yamada","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"R16-20250217","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.clgc.2015.07.015","article-title":"Sarcopenia evaluated using the skeletal muscle \u0131ndex \u0131s a significant prognostic factor for metastatic urothelial carcinoma","volume":"14","author":"Taguchi","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"R17-20250217","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","article-title":"Cancer cachexia in the age of obesity:Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index","volume":"31","author":"Martin","year":"2013","journal-title":"J Clin Oncol"},{"key":"R18-20250217","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.clnesp.2020.07.010","article-title":"The relationship between computed tomography derived skeletal muscle index, psoas muscle index and clinical outcomes in patients with operable colorectal cancer","volume":"39","author":"Abbass","year":"2020","journal-title":"Clin Nutr ESPEN"},{"key":"R19-20250217","doi-asserted-by":"crossref","first-page":"358","DOI":"10.21037\/atm.2020.02.49","article-title":"Low psoas muscle index associates with long-term mortality in cirrhosis:Construction of a nomogram","volume":"8","author":"Hou","year":"2020","journal-title":"Ann Transl Med"},{"key":"R20-20250217","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/jcsm.12349","article-title":"Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis","volume":"9","author":"Ebadi","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R21-20250217","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10388-019-00670-3","article-title":"Evaluation of the impact of psoas muscle index, a parameter of sarcopenia, in patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy","volume":"16","author":"Ozawa","year":"2019","journal-title":"Esophagus"},{"key":"R22-20250217","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1080\/10428194.2020.1856833","article-title":"Prognostic impact of the psoas muscle index, a parameter of sarcopenia, in patients with diffuse large B-cell lymphoma treated with rituximab-based chemoimmunotherapy","volume":"62","author":"Iltar","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"R23-20250217","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s11523-016-0430-0","article-title":"Sarcopenia and the Modified Glasgow Prognostic Score are Significant Predictors of Survival Among Patients with Metastatic Renal Cell Carcinoma Who are Receiving First-Line Sunitinib Treatment","volume":"11","author":"Ishihara","year":"2016","journal-title":"Target Oncol"},{"key":"R24-20250217","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1590\/s1677-5538.ibju.2019.0636","article-title":"Sarcopenia predicts prognosis of patients with renal cell carcinoma:A systematic review and meta-analysis","volume":"46","author":"Hu","year":"2020","journal-title":"Int Braz J Urol"},{"key":"R25-20250217","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.juro.2015.08.071","article-title":"Prognostic significance of sarcopenia in patients with metastatic renal cell carcinoma","volume":"195","author":"Fukushima","year":"2016","journal-title":"J Urol"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.ijc_649_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:27:05Z","timestamp":1787837225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.ijc_649_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_649_21","relation":{},"ISSN":["0019-509X","1998-4774"],"issn-type":[{"value":"0019-509X","type":"print"},{"value":"1998-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"2022-05-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}